中
Home
About Us
About Haihe Biopharma
Mission and Vision
Management Team
Company Milestones
Awards
Research & Development
Strong, Innovation-driven R&D Capabilities
R&D Pipeline
Investor Partnerships & BD
Investors
Business Development
News Center
News
Interview
Career
Our Culture
Salary and Benefits
Employee
Job
中文
日本語
News Center
Press Release
2025.11.07
Haihe Biopharma's innovative drug PARP1 inhibitor has obtained clinical trial approval in China
Today, Haihe Biopharma (Haihe), announced that the companys self-developed selective PARP1 inhibitor (R&D code: HH10...
2025.10.16
Haihe Biopharma Enters Into Exclusive License Agreement with Taiho Pharma for PI3Kα Inhibitor Risovalisib (CYH33)
Haihe Biopharma Co., Ltd. (hereinafter “Haihe”) and Taiho Pharmaceutical Co., Ltd. (hereinafter “Taiho”) (“HaiHe”)...
Press Release
2025.06.30
HaiHe Biopharma's Selective PI3Kα Inhibitor was Granted Orphan Drug Designation in Japan
2024.09.28
Haihe Biopharma Presented results of two clinical studies in 2024 CSCO Annual Meeting
2024.09.25
Haihe Biopharma Announces that Paclitaxel Oral Solution (RMX3001) was Approved by NMPA as Second-line Treatment for Gastric Cancer
2024.09.24
Haihe Biopharma and Taiho Pharmaceutical Announce the Launch of MET Inhibitor HAIYITAN® Tablets 50mg in Japan
2024.06.24
An innovative drug Gumarontinib (MET inhibitor) discovered and developed by Haihe Biopharma has been successfully approved in Japan
2024.06.03
Haihe Biopharma Presented results of two clinical studies in 2024 ASCO Annual Meeting
2024.04.07
Haihe Biopharma are presenting two drug discovery projects in 2024 AACR Annual Meeting
2024.03.01
Haihe Biopharma Enters Exclusive License Agreement with Taiho Pharma for Gumarontinib (SCC244), an Agent for Non-Small Cell Lung Cancer
1
2
3
Interview
|
Legal statement
|
Disclaimers
|
Contact
|
Follow Us
©
2020 All Rights Reserved Haihe Biopharma Co., Ltd.
沪ICP备12016151号-1
.jpg)
